Loxo Oncology
Loxo Oncology - Targeting Cancer with Strong Chemistry.
| Date | Investors | Amount | Round |
|---|---|---|---|
$33.0m | Series A | ||
$24.0m | Series B | ||
| N/A | $69.0m Valuation: $200m | IPO | |
* | N/A | $66.3m | Post IPO Equity |
* | N/A | $36.0m | Post IPO Equity |
* | N/A | $120m | Post IPO Equity |
* | N/A | $227m | Post IPO Equity |
* | $8.0b Valuation: $8.0b | Acquisition | |
| Total Funding | $57.0m | ||
| USD | 2015 | 2016 | 2017 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Loxo Oncology, a subsidiary of Eli Lilly and Company, focuses on the discovery and development of highly selective medicines aimed at treating genetically defined cancers. The company operates in the biotechnology and pharmaceutical sectors, targeting patients with specific genetic mutations that drive their cancer. Loxo Oncology's business model revolves around extensive research and development (R&D) to create a pipeline of targeted therapies, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated primarily through the sale of these specialized cancer treatments, as well as potential partnerships and collaborations with other biotech firms and research institutions. The company serves oncologists and healthcare providers who treat cancer patients, particularly those with rare or hard-to-treat genetic profiles. Loxo Oncology's market includes both domestic and international healthcare sectors, with a strong emphasis on innovation and precision medicine.
Keywords: oncology, genetically defined cancers, selective medicines, biotechnology, pharmaceutical, clinical trials, targeted therapies, precision medicine, Eli Lilly, cancer treatment.
